The role of disease stage in the response to donor lymphocyte infusions as treatment for leukemic relapse

Biology of Blood and Marrow Transplantation

Volumn 7, Issue 1, 2001, Pages 31-38

  Carlens, Stefan ^a   Remberger, Mats ^a   Aschan, Johan ^a   Ringdén, Olle ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Donor leukocyte infusion; Graft versus leukemia reaction; Relapse

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; INTERLEUKIN 2; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; PSORALEN; STEROID; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CHILD; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; DISEASE SEVERITY; DONOR; EARLY CANCER; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; IMMUNOPROPHYLAXIS; IMMUNOSUPPRESSIVE TREATMENT; INFUSION; LEUKEMIA; LEUKEMIA REMISSION; LYMPHOCYTE; MALE; MOLECULAR GENETICS; MYELODYSPLASTIC SYNDROME; PROBABILITY; PUVA; TREATMENT OUTCOME; WHOLE BODY RADIATION;

EID: 0035092803     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1053/bbmt.2001.v7.pm11215696     Document Type: Article

References (44)

1. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: A randomized trial of two irradiation regimens
2. Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: A randomized trial of two irradiation regimens
3. Second transplants for patients with chronic myeloid leukemia in relapse after original transplant with T-depleted donor marrow: Feasibility of using busulphan alone for re-conditioning
4. Second HLA-identical sibling transplants for leukemia recurrence
5. Relapse of leukemia after bone marrow transplantation: Effect of second myeloablative therapy
6. Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens
7. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts
8. Antileukemic effect of chronic graft-versus-host disease: Contribution to improved survival after allogeneic marrow transplantation
9. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia
10. Graft-versus-leukemia reactions after bone marrow transplantation
11. The highest leukemia-free survival after allogeneic bone marrow transplantation is seen in patients with grade I acute graft-versus-host disease: Acute and chronic leukemia working parties of the European Group Transplantation (EBMT)
12. Graft-versus-leukemia effect in allogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined with methotrexate as prophylaxis: Acute leukemia working party of the European marrow transplantation
13. Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms
14. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients
15. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: Separation of graft-versus-leukemia responses from graft-versus-host disease
16. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients: European group for blood and marrow transplantation working party chronic leukemia
17. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia
18. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation
19. Adoptive immunotherapy in bone marrow transplantation
20. Long-term follow-up of patients who achieved complete remission after donor leukocyte infusions
21. Prevention of graft-versus-host disease with T cell depletion or cyclosporin and methotrexate: A randomized trial in adult leukemic marrow recipients
22. Low incidence of acute graft-versus-host disease, using unrelated HLA-A-, HLA-B, and HLA-DR-compatible donors and conditioning, including anti-T-cell antibodies
23. Low-dose cyclosporine of short duration increases the risk of mild and moderate GVHD and reduces the risk of relapse in HLA-identical sibling marrow transplant recipients with leukemia
24. Lymphoblastoid human interferon and low dose IL-2 combined with donor lymphocyte infusion as therapy of a third relapse of CML: A case report
25. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation
26. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors
27. Management of graft-versus-host disease
28. Treatment of moderate to severe acute graft-versus-host disease: A retrospective analysis
29. Chronic graft-versus-host syndrome in man: A long-term clinicopathologic study of 20 Seattle patients
30. Autoanti-body analysis of patients with graft versus host disease
31. Design and analysis of randomized clinical trials requiring prolonged observation of each patient, II: Analysis and examples
32. Allogeneic bone marrow transplantation for leukemia: Factors of importance for long-term survival and relapse
33. Leukemia relapse after allogeneic bone marrow transplantation: A review
34. Risk factors in bone marrow transplant recipients with leukemia: Increased relapse risk in patients treated with ciprofloxacin for gut decontamination
35. Preliminary results of treatment with filgrastim for relapse of leukemia and myelodysplasia after allogeneic bone marrow transplantation
36. Risk factors for chronic graft-versus-host disease after bone marrow transplantation: A retrospective single centre analysis
37. Anti-leukemia potential of interleukin-2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemia
38. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia
39. Herpes-simplex thymidine-kinase-expressing donor T-cells administered with a T-cell depleted marrow graft: In vivo depletion of gene-modified donor T-cells
40. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation
41. Association of natural killer cell immune recovery with a graft-versus-leukemia effect independent of graft-versus-host disease following allogeneic bone marrow transplantation
42. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation
43. The potential role of NK cells in the separation of graft-versus-tumor effects from graft-versus-host disease after allogeneic bone marrow transplantation
44. Cell therapy: Achievements and perspectives